AACR 2019 – Baylor sets the benchmark for Bellicum
A Baylor College study suggests to investors what Bellicum’s upcoming first-in-human trial of BPX-603 will have to match.
The (unsung) best of Ash 2018
A top three of early-stage CAR-T presentations from this year’s Ash meeting that you might have missed.
Ash 2018 preview – blood cancers offer biotech a chance at redemption
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.
Zelluna joins the adoptive cell therapy chase
As the tiny Norwegian biotech gears up to put its first asset into the clinic, investors could use an ongoing trial to handicap its chances of success.
